company background image
AUPH

Aurinia PharmaceuticalsNasdaqGM:AUPH Stock Report

Last Price

US$16.26

Market Cap

US$2.1b

7D

-17.5%

1Y

9.4%

Updated

23 Jan, 2022

Data

Company Financials +
AUPH fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AUPH Stock Overview

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China.

Aurinia Pharmaceuticals Competitors

GlaxoSmithKline

LSE:GSK

UK£82.9b

Price History & Performance

Summary of all time highs, changes and price drops for Aurinia Pharmaceuticals
Historical stock prices
Current Share PriceUS$16.26
52 Week HighUS$33.97
52 Week LowUS$9.72
Beta0.69
1 Month Change-29.46%
3 Month Change-45.51%
1 Year Change9.42%
3 Year Change165.25%
5 Year Change404.97%
Change since IPO693.17%

Recent News & Updates

Nov 22

Aurinia Pharmaceuticals: Potential Blockbuster Justifies Big Pharma M&A Interest

Aurinia won approval for Lupus Nephritis therapy LUPKYNIS in January this year, causing its share price to reach a high of $19. Analysts believe the drug can achieve >$1bn per annum sales, and longer term, $2bn may not be unrealistic. That has created a slew of recent M&A rumours involving GSK, BMY, Roche, and Novartis - although a $250m mixed shelf filing suggests mgmt. may want to go it alone. The share price rose as high as $33 on the speculation - any acquisition could be at >$5bn, or ~$40 per share. I look at the pros and cons of buying Aurinia stock at current price of $20, market cap ~$2.7bn. I'd prefer an investment at a price closer to $15 per share.

Shareholder Returns

AUPHUS BiotechsUS Market
7D-17.5%-7.4%-6.1%
1Y9.4%-21.7%4.2%

Return vs Industry: AUPH exceeded the US Biotechs industry which returned -22% over the past year.

Return vs Market: AUPH exceeded the US Market which returned 4.2% over the past year.

Price Volatility

Is AUPH's price volatile compared to industry and market?
AUPH volatility
AUPH Average Weekly Movement14.0%
Biotechs Industry Average Movement10.2%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: AUPH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: AUPH's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a294Peter Greenleafhttps://www.auriniapharma.com

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.

Aurinia Pharmaceuticals Fundamentals Summary

How do Aurinia Pharmaceuticals's earnings and revenue compare to its market cap?
AUPH fundamental statistics
Market CapUS$2.11b
Earnings (TTM)-US$155.72m
Revenue (TTM)US$72.23m

29.2x

P/S Ratio

-13.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AUPH income statement (TTM)
RevenueUS$72.23m
Cost of RevenueUS$53.77m
Gross ProfitUS$18.46m
ExpensesUS$174.18m
Earnings-US$155.72m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.20
Gross Margin25.55%
Net Profit Margin-215.58%
Debt/Equity Ratio0%

How did AUPH perform over the long term?

See historical performance and comparison

Valuation

Is Aurinia Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AUPH ($16.26) is trading below our estimate of fair value ($121.94)

Significantly Below Fair Value: AUPH is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AUPH is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AUPH is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AUPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AUPH is overvalued based on its PB Ratio (7.1x) compared to the US Biotechs industry average (1.9x).


Future Growth

How is Aurinia Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

59.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AUPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: AUPH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AUPH's is expected to become profitable in the next 3 years.

Revenue vs Market: AUPH's revenue (43.6% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: AUPH's revenue (43.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AUPH's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Aurinia Pharmaceuticals performed over the past 5 years?

-27.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AUPH is currently unprofitable.

Growing Profit Margin: AUPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AUPH is unprofitable, and losses have increased over the past 5 years at a rate of 27% per year.

Accelerating Growth: Unable to compare AUPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AUPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: AUPH has a negative Return on Equity (-52.22%), as it is currently unprofitable.


Financial Health

How is Aurinia Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: AUPH's short term assets ($329.2M) exceed its short term liabilities ($37.5M).

Long Term Liabilities: AUPH's short term assets ($329.2M) exceed its long term liabilities ($24.4M).


Debt to Equity History and Analysis

Debt Level: AUPH is debt free.

Reducing Debt: AUPH has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AUPH has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AUPH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Aurinia Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AUPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AUPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AUPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AUPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AUPH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Peter Greenleaf (51 yo)

2.75yrs

Tenure

US$10,678,868

Compensation

Mr. Peter S. Greenleaf, M.B.A., has been President, Chief Executive Officer and Director of Aurinia Pharmaceuticals Inc. since April 29, 2019. Mr. Greenleaf has been a Director at Antares Pharma, Inc. sinc...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD10.68M) is above average for companies of similar size in the US market ($USD3.74M).

Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AUPH's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: AUPH's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AUPH insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.


Top Shareholders

Company Information

Aurinia Pharmaceuticals Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Aurinia Pharmaceuticals Inc.
  • Ticker: AUPH
  • Exchange: NasdaqGM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$2.108b
  • Shares outstanding: 129.67m
  • Website: https://www.auriniapharma.com

Number of Employees


Location

  • Aurinia Pharmaceuticals Inc.
  • 4464 Markham Street
  • Suite 1203
  • Victoria
  • British Columbia
  • V8Z 7X8
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 23:03
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.